Innovalve Bio Medical Ltd. פרסם מחדש את זה
First Major Exit - Over $300M in Less Than 4 Years! We're incredibly proud to share that our portfolio company, Innovalve Bio Medical Ltd. has been acquired by Edwards Lifesciences for over 300 $ million! Innovalve is a leading medical device company developing unique Transcatheter Mitral Valve Replacement (TMVR) technology. Invented at Sheba Medical Center, Israel's largest hospital, Innovalve is pioneering catheter-delivered heart valve therapies that promise to revolutionize cardiac care. Edwards Lifesciences, a global leader in heart care medical devices, has shown unprecedented confidence in this Israeli technology. This acquisition has the potential to reach millions of patients worldwide, save countless lives, and significantly improve global cardiac care. It's a testament to the power of Israeli innovation in healthcare. In the words of Michel Habib Founding Partner & Innovalve Board Member: “My partners and I are proud of achieving ALIVE Fund's first exit, based on our unique and focused investment strategy aimed at creating significant value in promising medical companies. Innovalve is a prime example of breakthrough Israeli technology developed by the best doctors and inventors in Israel, which has become a product and clinical success internationally with the active support of its board and investors throughout, leading to its sale to the world's leading company in heart valve technology." Thank you to our investors, partners, and the incredible Innovalve team for making this possible. Here's to advancing Israeli HealthTech and improving global healthcare! *** Alive focuses on investments in mature companies in the medical technology sector: → Exit achieved in under 4 years → Our portfolio includes 12 promising companies (e.g., Magenta Medical Ltd. Navina Cynerio → Now raising the next fund for continued investment in advanced healthcare technologies.